

## **Pneumococcal Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034**

Market Report | 2025-03-19 | 130 pages | Global Market Insights

### **AVAILABLE LICENSES:**

- Single User \$4850.00
- Multi User \$6050.00
- Enterprise User \$8350.00

### **Report description:**

The Global Pneumococcal Vaccine Market was valued at USD 8.8 billion in 2024 and is projected to grow at a CAGR of 5.6% between 2025 and 2034. Several factors are driving this growth, including the increasing prevalence of pneumococcal infections, rising public awareness about the importance of vaccination, and favorable government initiatives promoting immunization programs worldwide. The surge in vaccination rates can be attributed to growing efforts by healthcare authorities to implement mandatory vaccination schedules, particularly for children and high-risk populations. Ongoing advancements in research and development are leading to the production of more effective and innovative pneumococcal vaccines, catering to a wider range of serotypes. These vaccines play a crucial role in reducing the incidence of life-threatening conditions such as pneumonia, meningitis, and sepsis caused by *Streptococcus pneumoniae*.

As governments prioritize preventive healthcare and integrate pneumococcal vaccines into routine immunization schedules, market demand is set to rise significantly. The increasing focus on immunizing immunocompromised individuals and elderly populations is creating new opportunities for vaccine manufacturers. Furthermore, pharmaceutical companies are working closely with global health organizations to expand access to these vaccines in low-income regions, where pneumococcal diseases remain a major public health concern. Rising funding for vaccine research, coupled with initiatives to develop broad-spectrum vaccines that cover emerging serotypes, is expected to further boost market growth over the next decade.

The market is segmented based on product, with various pneumococcal vaccines contributing significantly to preventing severe bacterial infections. One of the most widely used vaccines is expected to experience notable growth, with a projected CAGR of 5.8%, generating USD 7.9 billion by 2034. Its proven efficacy in protecting against multiple *Streptococcus pneumoniae* serotypes has led to widespread adoption, especially in pediatric and high-risk adult populations. The vaccine's ability to provide long-term immunity makes it a preferred choice among healthcare providers and government vaccination campaigns. With its broad coverage against severe pneumococcal diseases, including pneumonia, sepsis, and meningitis, this vaccine continues to strengthen its position in global immunization programs.

The pneumococcal vaccine market is divided into two main types: conjugate vaccines and polysaccharide vaccines. Conjugate vaccines dominated the market in 2024, generating USD 8 billion due to their ability to offer long-lasting protection against

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

pneumococcal infections. Their high effectiveness in preventing pneumococcal diseases, especially among children under five years old, has fueled their growing demand. Additionally, expanding applications among adult populations, particularly those with weakened immune systems and elderly individuals, are accelerating the adoption of conjugate vaccines. Their ability to reduce the overall burden of pneumococcal diseases has established them as the preferred choice for routine immunization schedules. The U.S. pneumococcal vaccine market generated USD 3.7 billion in 2024. The rising elderly population in the country has been a key driver of this growth, as aging individuals face a higher risk of contracting pneumococcal infections due to declining immune function. Preventive healthcare efforts and nationwide vaccination programs have significantly increased vaccine uptake, ensuring better protection for high-risk populations. Pharmaceutical companies and government agencies continue to enhance vaccine coverage, with ongoing efforts to develop newer vaccines that target a broader range of pneumococcal serotypes, further supporting the market's long-term expansion.

## **Table of Contents:**

### Report Content

#### Chapter 1 Methodology And Scope

##### 1.1 Market scope and definitions

##### 1.2 Research design

###### 1.2.1 Research approach

###### 1.2.2 Data collection methods

##### 1.3 Base estimates and calculations

###### 1.3.1 Base year calculation

###### 1.3.2 Key trends for market estimation

##### 1.4 Forecast model

##### 1.5 Primary research and validation

###### 1.5.1 Primary sources

###### 1.5.2 Data mining sources

#### Chapter 2 Executive Summary

##### 2.1 Industry 360 synopsis

#### Chapter 3 Industry Insights

##### 3.1 Industry ecosystem analysis

##### 3.2 Industry impact forces

###### 3.2.1 Growth drivers

###### 3.2.1.1 Increasing prevalence of pneumococcal diseases

###### 3.2.1.2 Government immunization programs and initiatives

###### 3.2.1.3 Growing aging population

###### 3.2.1.4 Technological advancements and new product launches

###### 3.2.2 Industry pitfalls and challenges

###### 3.2.2.1 High cost of vaccines

###### 3.2.2.2 Vaccine hesitancy and low awareness

##### 3.3 Growth potential analysis

##### 3.4 Regulatory landscape

##### 3.5 Technology landscape

##### 3.6 Pipeline analysis

##### 3.7 Future market trends

##### 3.8 Gap analysis

##### 3.9 Porter's analysis

##### 3.10 PESTEL analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Chapter 4 Competitive Landscape, 2024

### 4.1 Introduction

### 4.2 Company market share analysis

### 4.3 Company matrix analysis

### 4.4 Competitive analysis of major market players

### 4.5 Competitive positioning matrix

### 4.6 Strategy dashboard

## Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 (\$ Mn)

### 5.1 Key trends

### 5.2 Pneumosil (PCV10)

### 5.3 Pneumovax 23 (PPSV23)

### 5.4 Prevnar 13 (PCV13)

### 5.5 Prevnar 20 (PCV20)

### 5.6 Synflorix (PCV10)

### 5.7 Vaxneuvance (PCV15)

### 5.8 Other products

## Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 (\$ Mn)

### 6.1 Key trends

### 6.2 Pneumococcal conjugate vaccines (PCV)

### 6.3 Pneumococcal polysaccharide vaccines (PPSV)

## Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 (\$ Mn)

### 7.1 Key trends

### 7.2 Infants and children (0-5 years)

### 7.3 Adults (18-64 years)

### 7.4 Elderly (65+ years)

## Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 (\$ Mn)

### 8.1 Key trends

### 8.2 Hospital pharmacies

### 8.3 Retail pharmacies

### 8.4 Government and public health agencies

### 8.5 E-commerce

## Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 (\$ Mn)

### 9.1 Key trends

### 9.2 North America

#### 9.2.1 U.S.

#### 9.2.2 Canada

### 9.3 Europe

#### 9.3.1 Germany

#### 9.3.2 UK

#### 9.3.3 France

#### 9.3.4 Spain

#### 9.3.5 Italy

#### 9.3.6 Netherlands

### 9.4 Asia Pacific

#### 9.4.1 China

#### 9.4.2 Japan

#### 9.4.3 India

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

9.6.3 UAE

Chapter 10 Company Profiles

10.1 Beijing Minhai Biological Technology

10.2 Bio-Manguinhos/Fiocruz

10.3 GlaxoSmithKline

10.4 Merck & Co.

10.5 Pfizer

10.6 Serum Institute of India

10.7 Walvax Biotechnology

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Pneumococcal Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis,  
and Forecast 2025 - 2034**

Market Report | 2025-03-19 | 130 pages | Global Market Insights

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$6050.00
	Enterprise User	\$8350.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

